DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec- 3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 2, 2004, Pages 783-792

  Valenzano, Kenneth J ^a,c   Miller, Wendy ^a   Chen, Zhengming ^a   Shan, Shen ^a   Crumley, Gregg ^a   Victory, Sam F ^a   Davies, Ellen ^a   Huang, Jin Cheng ^a   Allie, Nezima ^b   Nolan, Scott J ^b   Rotshteyn, Yakov ^b   Kyle, Donald J ^a   Broglé, Kevin ^a  

^a Purdue Pharma Discovery Research   (United States)

^b PURDUE PHARMA L P   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[8 (3,3 DIPHENYLPROPYL) 4 OXO 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DEC 3 YL]ACETIC ACID; DELTA OPIATE RECEPTOR; DIPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTREXONE; NOCICEPTIN; OPIATE RECEPTOR; OPIOID RECEPTOR LIKE 1 RECEPTOR; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SENSORY NERVE;

ACETIC ACIDS; ANALGESICS, OPIOID; ANIMALS; AZA COMPOUNDS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERALGESIA; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SPIRO COMPOUNDS;

EID: 3342892967     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.063313     Document Type: Article

References (44)

1. Abbruscato TJ, Thomas SA, Hruby VJ, and Davis TP (1997) Blood-brain barrier permeability and bioavailability of a highly potent and μ-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther 280:402-409.
2. Abdulla FA and Smith PA (1998) Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons. J Neurosci 18:9685-9694.
3. Abraham MH, Takacs-Novak K, and Mitchell RC (1997) On the partition of ampholytes: applications to blood-brain distribution. J Pharm Sci 86:310-315.
4. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
5. Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Hartig J, Mauler F, Minck K, Murray RD, Simon M, et al. (1994) A pharmacological profile of the novel, peripherally-selective K-opioid receptor agonist, EMD 61753. Br J Pharmacol 113:1317-1327.
6. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Cometta-Morini C, Maguire PA, and Loew GH (1992) Molecular determinants of μ receptor recognition for the fentanyl class of compounds. Mol Pharmacol 41:185-196.
8. DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Hagasaka H, Yu G, and Yaksh T (1999) Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 289:494-502.
9. Duggan AW and North RA (1983) Electrophysiology of opioids. Pharmacol Rev 35:219-281.
10. Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, and Medzihradsky F (1996) Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther 278:1121-1127.
11. i receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors. Eur J Pharmacol 336:233-242.
12. Fields HL and Basbaum AI (1999) Textbook of Pain (Wall PD and Melzack R ed) pp 309-343, Churchill Livingstone, Edinburg, UK.
13. Garrido MJ, Valle M, Calvo R, and Trocóniz IF (1999) Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther 288:179-187.
14. Gutstein HB and Akil H (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds) pp. 569-619, McGraw-Hill, New York.
15. Heykants J, Michiels M, Knaeps A, and Brugmans J (1974) Loperamide (R 18 553), a novel type of antidiarrheal agent. Arzneimittelforschung 24:1649-1653.
16. Herz A, ed. (1993) Handbook of Experimental Pharmacology: Opioids, vol 104/I, Springer-Verlag, Berlin, Germany.
17. Ingram SL and Williams JT (1994) Opioid inhibition of Ih via adenylyl cyclase. Neuron 13:179-186.
18. Kalso E, Tramer MR, Carroll D, McQuay HJ, and Moore RA (1997) Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review. Pain 71:127-134.
19. Ko MCH, Naughton NN, Traynor JR, Song MS, Woods JH, Rice KC, and McKnight AT (2002) Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br J Pharmacol 135:943-950.
20. Koob GF and Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science (Wash DC) 242:715-723.
21. Likar R, Sittl R, Gragger K, Pipam W, Blatnig H, Breschan C, Schalk HV, Stein C, and Schafer M (1998) Peripheral morphine analgesia in dental surgery. Pain 76:145-150.
22. Machelska H, Binder W, and Stein C (1999a) Opioid Sensitivity of Chronic Non-cancer Pain (Kalso E, McQuay H, and Wiesenfeld-Hallin Z eds) pp 45-58, IASP Press, Seattle, WA.
23. Machelska H, Pflüger M, Weber W, Piranvisseh-Volk M, Daubert JD, Dehaven R, and Stein C (1999b) Peripheral effects of the K-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 290:354-361.
24. Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, Tian M, Schulman H, and Yu L (1995) The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci 15:2396-2406.
25. Mousa SA (2003) Morphological correlates of immune-mediated peripheral opioid analgesia. Adv Exp Med Biol 521:77-87.
26. Pleuvry BJ (2003) Update on opioids. Curr Anaesth Crit Care 14:155-159.
27. Raynor K, Kong H, Chen Y, Yasude K, Yu L, Bell GI, and Reisine T (1994) Pharmacological characterization of the cloned kappa-, delta- and mu-opioid receptors. Mol Pharmacol 45:330-334.
28. Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J, Yu L, and Reisine T (1995) Characterization of the cloned human mu opioid receptor. J Pharmacol Exp Ther 272:423-428.
29. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, and Erlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (Wash DC) 239:487-491.
30. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
31. Selley DE, Breivogel CS, and Childer SR (1993) Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins. Mol Pharmacol 44:731-741.
32. Shannon HE and Lutz EA (2002) Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. Neuropharmacology 42:253-261.
33. Stanski DR (1987) Narcotic pharmacokinetics and dynamics: the basis of infusion applications. Anaesth Intensive Care 15:23-26.
34. Stein A, Yassouridis A, Szopko C, Helmke K and Stein C (1999) Intraarticular morphine versus dexamethasone in chronic arthritis. Pain 83:525-532.
35. Stein C, Millan MJ, Shippenberg TS, and Herz A (1988) Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci Lett 84:225-228.
36. Stein C, Schäffer M, and Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9:1003-1008.
37. Terenius L (2000) From opiate pharmacology to opioid peptide physiology. Upsala J Med Sci 105:1-16.
38. Victory SF and Chen Z (2003) inventors, Euro-Celtique SA, assignee. Triazaspiro compounds useful for treating or preventing pain. WO patent 03101953. 2003 Dec 11.
39. Wang H and Wessendorf MW (2001) Equal proportions of small and large DRG neurons express opioid receptor mRNAs. J Comp Neurol 429:590-600.
40. Wenk HN, Nannenga MN, and Honda CN (2003) Effect of morphine sulphate eye drops on hyperalgesia in the rat cornea. Pain 105:455-465.
41. Whiteside GT, Harrison JE, Pearson MS, Chen Z, Rotstheyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, and Brogle K (2004) DiPOA ([8-(3,3-diphenyl- propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid), a novel, systemically-available and peripherally-restricted mu opioid agonist with anti-hyperalgesic activity: II. In vivo pharmacological characterization in the rat. J Pharmacol Exp Ther 310:793-799.
42. Yaksh TL (1999) Textbook of Pain (Wall PD and Melzack R eds) pp 253-308, Churchill Livingstone, Edinburg, UK
43. Yoshida K, Nambu K, Arakawa S, Miyazaki H, and Hashimoto M (1979) Metabolites of loperamide in rats. Biomed Mass Spectrom 6:253-259.
44. Zöllner C, Shaqura MA, Bopaiah CP, Mousa S, Stein C, and Schäfer M (2003) Painful inflammation-induced increase in μ-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 64:202-210.